Atlas Trials

MPN (Myeloproliferative Neoplasms)

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch MPN (Myeloproliferative Neoplasms)

RecordFirmDate
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation (NCT06892223)Istituto Clinico Humanitas2021-12-03
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis (NCT03144687)Incyte Corporation2018-01-26
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) (NCT03123588)Incyte Corporation2017-11-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) (NCT03011372)Incyte Corporation2017-04-25
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis (NCT02718300)Incyte Corporation2017-02-08
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) (NCT02953704)Incyte Corporation2016-12-31
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) (NCT02252159)Incyte Corporation2014-07-31
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis (NCT01633372)Incyte Corporation2012-07-16
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) (NCT01348490)Incyte Corporation2011-06-15
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial (NCT00952289)Incyte Corporation2009-08-01

Track MPN (Myeloproliferative Neoplasms) automatically

Every clearance here is in the API, with alerts when new ones post.